Warning (512): /home/pharma/website/current/cakephp/app/pharmalicensing/tmp/cache/ is not writable [CORE/cake/libs/cache/file.php, line 267]
Code
        if ($this->_init && !is_writable($this->settings['path'])) {
            $this->_init = false;
            trigger_error(sprintf(__('%s is not writable', true), $this->settings['path']), E_USER_WARNING);
FileEngine::__active() - CORE/cake/libs/cache/file.php, line 267
FileEngine::init() - CORE/cake/libs/cache/file.php, line 94
Cache::_buildEngine() - CORE/cake/libs/cache.php, line 151
Cache::config() - CORE/cake/libs/cache.php, line 126
include - /home/pharma/website/releases/20120317114903/cakephp/app/pharmalicensing/config/core.php, line 345
Configure::__loadBootstrap() - CORE/cake/libs/configure.php, line 391
Configure::getInstance() - CORE/cake/libs/configure.php, line 52
include - CORE/cake/bootstrap.php, line 38
[main] - /home/pharma/website/releases/20120317114903/cakephp/webroot/pharmalicensing/index.php, line 100

• Home
• Licensing Center
  • Data Center
    • Out-licensing
    • In-licensing
    • Companies
    • Services
  • Reports
  • Newsletter
    • Subscribe
    • Partnering Update
    • Key Reports
    • Pharmalicensing Recommends
  • Pharmalicensing Intelligence
    • Industry News
    • Deals Review
    • Press Releases
    • Articles
  • Profiled Companies
  • Events
• Our Services
  • Partnering Search
  • Company Profiling
  • Reports
  • Pharma Transfer
  • Deal Negotiation
  • Pharmalicensing Intelligence
• About us
  • Case Studies
  • Our Audience
  • FAQ
  • Directions
  • MedicalDeviceLicensing.com
  • Innovaro Corporate
• Contact us

Login    Register

Search

Industry news

• Industry news
• Genitourinary

News of the day

Affymax and Takeda Announce Preliminary U.S. Registration Strategy for Investigational Drug, Hematide(TM)/Peginesatide, to Treat Anemia in Chronic Renal Failure

PALO ALTO, Calif. & OSAKA, Aug 05, 2010 -- Affymax, Inc. (Nasdaq:AFFY) and Takeda Pharmaceutical Company Limited (TSE:4502), today announced that the companies have decided on a preliminary strategic path forward for the investigational drug, Hematide(TM)/peginesatide, for the treatment of anemia in chronic renal failure patients in the United States. more

Industry news search

Search the Innovaro Pharmalicensing Industry news by keyword. Alternatively our advanced search allows you to query by category and therapeutic target.
Category	Therapeutic target
Deals and Alliances Development Financial Results Financings Intellectual Property Regulatory	Cardiovascular Dermatology Endocrine and Metabolic Gastroenterology Genitourinary Hematology Immunology and Allergy Infection Musculoskeletal Neurology Obstetrics and Gynecology Oncology Ophthalmology Psychiatry Pulmonary
To choose more then one item on the list hold CTRL button while selecting. To deselect items press CTRL button and deselect.

Most Viewed

Affymax and Takeda Announce Preliminary U.S. Registration Strategy for Investigational Drug, Hematide(TM)/Peginesatide, to Treat Anemia in Chronic Renal Failure

Recent news

To keep up to date with news from this category use our

Products:	Partnering Search	Company Profiling	Pharmalicensing Intelligence	Reports	Comparision
In-licensing:	Latest records	Industry Sector	Therapeutic Target	Search	Profile your company	Pharma partnering
Out-licensing:	Latest records	Industry Sector	Therapeutic Target	Search	Profile your company	Pharma partnering
Companies:	Profiled companies	Industry Sector	Therapeutic Target	Geographic Location	Search	Add your company
Reports:	Biotechnology	Business Development	Management	Market & Sales	Medical Devices	Pharmaceuticals
News:	Deals & Alliances	Development	Financial Results	Financings	Intellectual Property	Regulatory
Events:	Pharma events	Calendar	Organizers	Featured events	Search
Articles:	Industrial Sector	Therapeutic Target	Articles date
Deals:	Industry Sector	Therapeutic Target	Deals Date	Search	Reports	Press releases
About us:	Our Audience	Case Studies	Newsletter	FAQ	Contact us	Site map

© Copyright 1998-2012 Innovaro Europe Ltd All rights reserved. Terms and Conditions | Contact us